Bayer: Dermatitis, Atopic trials
The registry lists 14 Dermatitis, Atopic studies with Bayer as lead sponsor. 0 are open to participants now and 1 have results posted.
Phase 2 7Phase 4 1No phase 6(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study to Learn How Well the Study Treatment Zabedosertib (BAY1834845) Works and How Safe it is Compared to Placebo in Adult Participants With Moderate-to-severe Atopic DermatitisCompletedNCT05656911Phase 2Results posted
- An Observational Study to Gather Real-World User Feedback on DIPROBASE® Advanced Eczema Cream in Adults and Children With Eczema or Dry SkinCompletedNCT06747897
- Functional Study to Investigate the Efficacy of a New Medical Device (Modified Diprobase Formulation)CompletedNCT03672383Not applicable
- In-home Use Test of the New Modified Diprobase Formulation to Assess the Safety and Tolerability in Infants and Children Under Physician's ControlCompletedNCT03441568Not applicable
- Curing Atopic Dermatits in Children With a Commerical Medical Device and Maintaining Healthy Skin by Using a New Cosmetic ProductCompletedNCT02615561Not applicable
- Efficacy/Safety Study to Explore a New Revised Topical Formulation in Atopic DermatitisCompletedNCT01948869Not applicable
- Efficacy/Safety Study to Explore a New Topical Formulation in Atopic DermatitisWithdrawnNCT01691209Not applicable
- HPA Axis Study in AdultsCompletedNCT01408511Phase 2
- HPA Axis Study in Japanese AdultsCompletedNCT01407510Phase 2
- Efficacy and Safety of Different Concentrations of Mapracorat Ointment Over 4 Weeks in Atopic Dermatitis (AD)CompletedNCT01359787Phase 2
- Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD)CompletedNCT01228513Phase 2
- Sinecort Pilot Efficacy StudyCompletedNCT00980135Phase 2
- Dose Escalation of Different Concentrations of ZK 245186 in Atopic DermatitisCompletedNCT00944632Phase 2
- A Clinical Study in Children and Adolescents With Mild to Moderate Atopic DermatitisCompletedNCT00568412Phase 4